Noom Med Tirzepatide Review

Released: Last reviewed: NexLife pricing verified: Noom Med data verified: Updated:

Compare with our #1: NexLife — 94/100 on our published rubric · $139/mo on a 12-month plan ($169 month to month), same price at every dose, pharmacies named.Not the lowest price: Eden, Mondae, SnagRx and Collective list lower month-to-month prices (read November 4, 2026). Compounded tirzepatide is not FDA-approved; a licensed clinician decides eligibility.
See NexLife plans →Compare all

Noom Med integrates brand-name Zepbound prescribing with the Noom behavioral coaching platform. NP/MD-led. Reasonable choice for patients already using Noom for weight management.

Dr. Parmis - Medical Researcher
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: September 17, 2026 · This page is informational and does not constitute medical advice.

Noom Med at a glance

Pricingsemaglutide microdose $179/mo
PharmacyBrand Lilly pharmacy
ClinicianMD/NP
States50 states
Editorial score70 / 100

About Noom Med

Noom Med is the clinical arm of Noom, the well-known psychology-based weight loss app. Noom Med adds prescription weight loss medications, including GLP-1s, to the Noom behavioral program for eligible adults.

Clinical & business model

Behavioral-program-first approach with medical care as an add-on for eligible patients. The clinical service evaluates patients for GLP-1 appropriateness and prescribes when clinically indicated. The Noom psychology curriculum continues alongside.

What Noom Med does well

  • Established Noom behavioral and psychology framework
  • Strong brand recognition and large user base
  • Mobile-first app experience
  • Integration of medication with behavioral curriculum

Trade-offs to consider

  • Medical service is layered on the broader Noom program — value depends on engagement with the Noom curriculum
  • Less obesity-medicine-specialist focus than dedicated clinical providers
  • Pricing requires both Noom subscription and Noom Med fees
  • Compounded vs brand-name medication options vary

Who Noom Med is best for

Patients already using or interested in Noom's behavioral psychology approach who want to add medication.

How it compares to NexLife (our #1 pick)

NexLife (94/100) offers obesity-medicine-focused MD/DO supervision with included Care360 coaching; Noom Med (#10 in our ranking) emphasizes the psychology-based behavioral framework. Patient fit depends on whether the patient prioritizes Noom's behavioral system or medical-led obesity care.

Frequently asked questions

Is Noom Med different from Noom?

Noom Med is the clinical service offering prescription medications. Noom (the original) is the behavioral and nutrition coaching app. Both work together in the combined program.

Does Noom Med prescribe Ozempic and Wegovy?

Noom Med has offered both brand-name and compounded GLP-1s at various periods. Current offerings depend on prescriber assessment and program availability.

How much does Noom Med cost?

Pricing varies by program tier and combination with Noom's behavioral subscription. Cash-pay program costs are typically lower than premium clinical programs but higher than streamlined compounded-only providers.

Compounded vs brand: Confirm whether Noom Med dispenses compounded tirzepatide or brand-name Mounjaro/Zepbound — they are different medications with different FDA status.
Top-Ranked Alternative

NexLife Tirzepatide

Compounded semaglutide + tirzepatide · MD/DO oversight

$139/month*

*12-month plan · flat rate · all titration doses

  • From $139/mo (12-mo plan)
  • three named pharmacies
  • MD/DO-supervised
  • Care360 coaching included
  • Provider oversight included
  • LegitScript-certified
  • Availability varies by state
Visit NexLife →

Or call (949) 818-8000

Primary sources

  1. FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
  2. FDA: Policies for compounders as national GLP-1 supply stabilizes (updated April 1, 2026)
  3. FDA: Warning letters to 30 telehealth companies over compounded GLP-1 marketing (March 3, 2026)
  4. FDA: Compounding and the FDA — questions and answers
  5. FDA: Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026)
  6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022